Statute Details
- Title: Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007
- Act Code: HPA2007-S683-2007
- Type: Subsidiary Legislation (SL)
- Enacting Authority: Health Sciences Authority (with Minister for Health approval)
- Authorising Act: Health Products Act 2007 (notably section 72)
- Commencement: 1 January 2008
- Current Version: Current version as at 27 Mar 2026 (per provided status)
- Key Parts: Part I (Preliminary); Part II (Supply of Cosmetic Products); Part III (Advertisement of Cosmetic Products); Part IV (Additional Duties and Obligations)
- Key Definitions (Extract): Section 2 (definitions, including “cosmetic product”)
- Key Scope Provision (Extract): Section 3 (application/exclusions)
- Notable Operational Duties (from table of provisions): Sections 4, 6, 7, 8, 9, 10, 11
- Schedules: First and Second Schedules (repealed); Fourth Schedule (standard references for cosmetic ingredient nomenclature)
What Is This Legislation About?
The Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 (“Cosmetic Products Regulations”) are Singapore’s regulatory framework for cosmetic products, designed to align with the ASEAN Cosmetic Directive approach. In practical terms, the Regulations set out compliance requirements for how cosmetic products are supplied, labelled, advertised, and monitored in the Singapore market.
Although cosmetics are often perceived as lower-risk than medicines, the Regulations treat them as regulated consumer products because cosmetic ingredients and claims can affect public health and consumer welfare. The Regulations therefore impose duties on the “person responsible” for placing a cosmetic product on the market, including notification to the Health Sciences Authority (HSA), requirements for product contents and labelling, controls on misleading labelling, and obligations to maintain records and report defects/adverse effects.
The Regulations also clarify the boundaries of their application. They do not apply to cosmetic products imported solely for re-export or manufactured solely for export. This ensures that the compliance burden is directed to products that are actually made available for sale in Singapore, rather than those merely passing through or being produced for foreign markets.
What Are the Key Provisions?
Part I: Preliminary—citation, definitions, and application
Section 1 (Citation and commencement) provides the legal identity of the Regulations and confirms that they came into operation on 1 January 2008. For practitioners, this matters when assessing historical compliance and determining which version of the regulatory regime applied at a given time.
Section 2 (Definitions) is central to interpreting the Regulations. The extract defines “cosmetic product” by reference to the definition in the First Schedule to the Health Products Act 2007. This incorporation-by-reference technique means that the scope of “cosmetic product” is not determined solely by the Regulations themselves; it depends on the Act’s schedule and any amendments to it. The definition also reflects that the Regulations are meant to regulate a defined category of products rather than any consumer product marketed as “cosmetic”.
Section 2 also introduces a key compliance concept: the “person responsible” for placing a cosmetic product in the market is the person in Singapore who is instrumental in causing the product to be available for sale in Singapore. This is a practical hook for enforcement: regulators need a Singapore-based accountable party, not merely an overseas manufacturer.
Section 3 (Application) sets out exclusions. The Regulations do not apply to a cosmetic product that is:
- imported into Singapore solely for re-export; or
- manufactured in Singapore solely for export.
This provision is important for supply-chain structuring. If a company imports or manufactures for export only, it may avoid the Singapore cosmetic compliance regime—provided the facts genuinely support “solely” re-export/export. Mixed commercial arrangements (for example, goods imported for re-export but later sold locally) can create compliance risk.
Part II: Supply of cosmetic products—notification, contents, and labelling
Section 4 (Duty to notify Authority of supply of cosmetic products) establishes a notification obligation. While the extract does not reproduce the full text of Section 4, the heading indicates that the “person responsible” (or another specified party) must notify HSA when supplying cosmetic products in Singapore. In practice, such notification regimes typically require submission of product particulars and may operate as a gatekeeping mechanism for market access.
Section 6 (Contents of cosmetic products) signals that cosmetic products must meet substantive requirements regarding their ingredients and composition. This is where ingredient restrictions, permitted substances, and safety-related standards usually sit. For counsel advising product formulation or ingredient changes, Section 6 is a key compliance anchor: it is not enough that a product is labelled attractively; it must also be legally compliant in its composition.
Section 7 (Labelling of cosmetic products) requires compliant labelling. Labelling provisions typically cover matters such as ingredient listing, net contents, identification of the responsible party, and other mandatory particulars. For practitioners, labelling is often the most visible compliance area and the one most likely to be scrutinised in consumer complaints and enforcement actions.
Section 8 (Misleading labelling) addresses false or deceptive labelling. Even where a label includes required information, it may still be unlawful if it misleads consumers—for example, by implying medical effects, overstating efficacy, or using claims that are not supported by the product’s nature and composition. This provision is particularly relevant for marketing teams and regulatory affairs professionals because it links labelling compliance to consumer protection principles.
Part III: Advertisement of cosmetic products
Section 9 (Advertisement of cosmetic products) extends regulatory control beyond the physical product label to advertising. Cosmetic advertising can create regulatory exposure through claims made in brochures, e-commerce listings, social media posts, and influencer campaigns. Section 9 therefore matters for legal review of advertising copy, promotional materials, and digital marketing content.
In practice, advertisement controls often operate alongside labelling controls to prevent misleading claims and to ensure that advertising does not circumvent product labelling requirements. For lawyers, Section 9 is a reminder that compliance is not limited to packaging; it also includes how the product is presented to the public.
Part IV: Additional duties and obligations—records and safety reporting
Section 10 (Duty to maintain records of supply) requires regulated parties to keep records. Record-keeping duties are crucial for traceability, investigations, and demonstrating compliance. They also support recall management and help regulators assess whether a product was supplied in accordance with the Regulations.
Section 11 (Reporting of defects and adverse effects to Authority) imposes a safety surveillance obligation. Again, the extract does not reproduce the detailed mechanics, but the heading indicates that when defects or adverse effects occur, the responsible party must report to HSA. This kind of obligation is a cornerstone of post-market regulation: it shifts the regulatory focus from pre-market compliance alone to ongoing monitoring and responsiveness.
For practitioners, Section 11 is particularly important in advising on incident response protocols: how to triage complaints, determine whether an adverse effect is reportable, document the assessment, and meet reporting timelines.
How Is This Legislation Structured?
The Regulations are organised into four Parts and multiple Schedules.
Part I (Preliminary) contains the foundational provisions: citation and commencement (Section 1), definitions (Section 2), and application/exclusions (Section 3).
Part II (Supply of Cosmetic Products) sets out the core market-access and product compliance requirements, including notification (Section 4), substantive content rules (Section 6), labelling requirements (Section 7), and prohibitions on misleading labelling (Section 8). Section 5 is indicated as deleted in the provided table of provisions.
Part III (Advertisement of Cosmetic Products) contains a single key provision (Section 9) governing advertising.
Part IV (Additional Duties and Obligations) imposes ongoing compliance duties: record maintenance (Section 10) and reporting of defects/adverse effects (Section 11).
In terms of Schedules, the First and Second Schedules are shown as repealed, while the Fourth Schedule relates to standard references used for cosmetic ingredient nomenclature. This is significant for ingredient listing accuracy and consistency, especially when ingredient names must follow recognised nomenclature standards.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in supplying cosmetic products in Singapore, with compliance anchored to the concept of the person responsible. As defined in Section 2, the person responsible is the Singapore person instrumental in causing the cosmetic product to be available for sale in Singapore. This typically includes local importers, distributors, or other Singapore-based entities that take operational responsibility for market placement.
However, the Regulations do not apply to cosmetic products imported solely for re-export or manufactured solely for export (Section 3). Accordingly, companies engaged only in transit/re-export or export-only manufacturing may not be subject to these specific Singapore cosmetic compliance duties, provided their activities remain within the statutory exclusions.
Why Is This Legislation Important?
For legal practitioners and regulatory affairs counsel, the Cosmetic Products Regulations are important because they translate the ASEAN-aligned approach into enforceable Singapore obligations. They create a structured compliance pathway covering pre-market and post-market aspects: notification, content and labelling compliance, advertising controls, record-keeping, and safety reporting.
From an enforcement and risk perspective, the Regulations provide HSA with multiple points of intervention. Non-compliant labelling or misleading claims can trigger action even if the product’s ingredients are otherwise acceptable. Similarly, failure to maintain records or to report adverse effects can create liability even when a product was initially compliant at the time of supply.
The Regulations also have practical implications for corporate structuring and contracting. Because the “person responsible” is defined by Singapore-based instrumental involvement, businesses must ensure that responsibility is correctly allocated in distribution agreements, import arrangements, and marketing contracts. Misalignment between contractual responsibility and regulatory responsibility can lead to compliance gaps and disputes during investigations or incidents.
Finally, the amendment timeline provided indicates that the Regulations have been actively updated over time (for example, amendments in 2019, 2022, 2023, 2024, and 2025). Practitioners should therefore treat compliance as a moving target: ingredient nomenclature, definitions, and operational requirements may change, and counsel should verify the current version applicable to the product lifecycle stage.
Related Legislation
- Health Products Act 2007 (Act 15 of 2007) — authorising framework and definition of “cosmetic product” via the First Schedule
- Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 — this subsidiary legislation
Source Documents
This article provides an overview of the Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.